Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Vassal

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
International Journal of Cancer|October 23, 1997
Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude miceG Vassal, I Boland, A Santos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 3, 2021
Access to essential anticancer medicines for children and adolescents in EuropeG Vassal, O Kozhaeva, S Griskjane, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastomaE Raymond, M Fabbro, V Boige, et al.
Cancer Chemotherapy and Pharmacology|March 30, 2007
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoringG Vassal, G Michel, H Espérou, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 21, 1999
Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?A Le Cesne, G Vassal, F Farace, et al.
British Journal of Cancer|August 5, 2004
No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecanL Calvet, A Santos, A Valent, et al.
British Journal of Cancer|August 1, 1996
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenograftsG Vassal, M J Terrier-Lacombe, M C Bissery, et al.
AJNR. American Journal of Neuroradiology|March 2, 2019
Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade GliomasD Rodriguez, T Chambers, M Warmuth-Metz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2002
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup StudyL S Lashford, P Thiesse, A Jouvet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activityG Vassal, I Boland, M J Terrier-Lacombe, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
International Journal of Cancer|October 23, 1997
Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude miceG Vassal, I Boland, A Santos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 3, 2021
Access to essential anticancer medicines for children and adolescents in EuropeG Vassal, O Kozhaeva, S Griskjane, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastomaE Raymond, M Fabbro, V Boige, et al.
Cancer Chemotherapy and Pharmacology|March 30, 2007
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoringG Vassal, G Michel, H Espérou, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 21, 1999
Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?A Le Cesne, G Vassal, F Farace, et al.
British Journal of Cancer|August 5, 2004
No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecanL Calvet, A Santos, A Valent, et al.
British Journal of Cancer|August 1, 1996
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenograftsG Vassal, M J Terrier-Lacombe, M C Bissery, et al.
AJNR. American Journal of Neuroradiology|March 2, 2019
Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade GliomasD Rodriguez, T Chambers, M Warmuth-Metz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2002
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup StudyL S Lashford, P Thiesse, A Jouvet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activityG Vassal, I Boland, M J Terrier-Lacombe, et al.
Pageof 10